Literature DB >> 33604763

Evaluation of temporomandibular joint disorder in headache patients.

Fergane Memmedova1, Ufuk Emre2, Osman Özgür Yalın2, Onur Can Doğan3.   

Abstract

OBJECTIVE: The present study is aimed at determining the percentage of temporomandibular joint disorder (TMD) in patients admitted to the neurology outpatient clinic with a headache complaint and to evaluate the association of TMD with the presence of bruxism and headache traits.
MATERIALS AND METHODS: A total of 349 headache patients were included in the study. The headache type, characteristics of the headache (incidence, duration, and severity of attacks), and the scores of the migraine disability scale (MIDAS) and Allodynia Symptom Scale (ASC-12T) were examined considering the presence of sleep bruxism. The International Classification of Headache Disorders (ICHD-3 Beta) criteria were used for diagnosing headaches. The presence of TMD was evaluated by using the Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD). All patients diagnosed with TMD and/or bruxism were evaluated by a dentist.
RESULTS: A total of 349 patients, 259 females and 90 males, were included in the study. The mean age of the patients was 36 years. Primary and secondary headaches were diagnosed in 317 (90.80%) and 32 (9.20%) patients, respectively. In the primary headache group, there were 227 migraines (182 females, 45 males), 74 tension-type headaches (TTH) (48 females, 26 males), and 15 trigeminal autonomic cephalalgias (TACs) (7 females, 8 males) patients. The remaining patients were diagnosed with other types of diagnoses. The rate of patients with chronic headache was 86.50%. TMD was detected in 89 (25.50%) of the patients while sleep bruxism was present in 80 (23.30%) patients. TMD was detected in 68 (30.0%) migraine patients and 13 (17.60%) TTH patients. The rate of TMD was statistically significantly higher in migraine patients compared to the TTH patients (p=0.037).
CONCLUSION: Our cross-sectional outpatient-based study determined the incidence of TMD in headache patients as 25%. Among the primary headaches, the incidence of TMD was higher in migraine patients compared to the other diagnoses. Considering these data, the presence of TMD is a clinical condition that should be considered in the pathophysiology of headache, primarily migraine, and especially in cases of non-response to treatment.

Entities:  

Keywords:  Bruxism; Headache; Migraine; TMD

Year:  2021        PMID: 33604763     DOI: 10.1007/s10072-021-05119-z

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  5 in total

1.  Managing a patient with sleep bruxism.

Authors:  Kelvin I Afrashtehfar; Cyrus D M Afrashtehfar; Nelly Huynh
Journal:  J Can Dent Assoc       Date:  2014       Impact factor: 1.316

2.  Painful temporomandibular disorders and headaches in 359 dental and medical students.

Authors:  Rafael Benoliel; Gal Sela; Sorin Teich; Yair Sharav
Journal:  Quintessence Int       Date:  2011-01       Impact factor: 1.677

3.  Migraine is the most prevalent primary headache in individuals with temporomandibular disorders.

Authors:  Ana L Franco; Daniela A G Gonçalves; Sabrina M Castanharo; José G Speciali; Marcelo E Bigal; Cinara M Camparis
Journal:  J Orofac Pain       Date:  2010

4.  Temporomandibular disorders, sleep bruxism, and primary headaches are mutually associated.

Authors:  Giovana Fernandes; Ana Lúcia Franco; Daniela Aparecida Gonçalves; José Geraldo Speciali; Marcelo Eduardo Bigal; Cinara Maria Camparis
Journal:  J Orofac Pain       Date:  2013

Review 5.  Topical review: sleep bruxism and the role of peripheral sensory influences.

Authors:  Takafumi Kato; Norman M Thie; Nelly Huynh; Shouichi Miyawaki; Gilles J Lavigne
Journal:  J Orofac Pain       Date:  2003
  5 in total
  1 in total

1.  Headache Because of Problems with Teeth, Mouth, Jaws, or Dentures in Chronic Temporomandibular Disorder Patients: A Case-Control Study.

Authors:  Tadej Ostrc; Sabina Frankovič; Zvezdan Pirtošek; Ksenija Rener-Sitar
Journal:  Int J Environ Res Public Health       Date:  2022-03-05       Impact factor: 3.390

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.